Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab

European Journal of Cancer

Volumn 51, Issue 14, 2015, Pages 2086-2094

  Valpione, S ^a   Martinoli, C ^b   Fava, P ^c   Mocellin, S ^d   Campana, L G ^a   Quaglino, P ^c   Ferrucci, P F ^b   Pigozzo, J ^a   Astrua, C ^c   Testori, A ^b   Chiarion Sileni, V ^a  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

Author keywords

Immunotherapy; Ipilimumab; Metastatic melanoma; Nomogram; Prognostic model

Indexed keywords

ALKALINE PHOSPHATASE; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; INTERLEUKIN 2; INTERLEUKIN 6; IPILIMUMAB; LACTATE DEHYDROGENASE; PROTEIN S 100; VASCULOTROPIN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TUMOR MARKER;

ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER SURVIVOR; CENTRAL NERVOUS SYSTEM METASTASIS; FEMALE; FOLLOW UP; GLOBULIN BLOOD LEVEL; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; MULTIPLE CYCLE TREATMENT; NEUTROPHIL; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SURVIVAL PREDICTION; SURVIVAL RATE; SYSTEMIC THERAPY; VALIDATION STUDY; BLOOD; CLINICAL TRIAL; DECISION SUPPORT SYSTEM; DISEASE FREE SURVIVAL; ITALY; KAPLAN MEIER METHOD; LYMPHOCYTE COUNT; MELANOMA; MORTALITY; MULTICENTER STUDY; NOMOGRAM; PATHOLOGY; PATIENT SELECTION; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; REPRODUCIBILITY; RISK FACTOR; SECONDARY; SKIN NEOPLASMS; TIME; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DECISION SUPPORT TECHNIQUES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; ITALY; KAPLAN-MEIER ESTIMATE; LYMPHOCYTE COUNT; MALE; MELANOMA; NEOPLASM RECURRENCE, LOCAL; NOMOGRAMS; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SKIN NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84939573580     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.06.130     Document Type: Article

References (33)

1. E.L. Korn, P.Y. Liu, S.J. Lee, J.A. Chapman, D. Niedzwiecki, V.J. Suman, and et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials J Clin Oncol 26 4 2008 527 534
2. V.A. Boussiotis Somatic mutations and immunotherapy outcome with CTLA-4 blockade in melanoma N Engl J Med 371 23 2014 2230 2232
3. M.S. Lawrence, P. Stojanov, P. Polak, G.V. Kryukov, K. Cibulskis, A. Sivachenko, and et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes Nature 499 7457 2013 214 218
4. M. Maio, J.J. Grob, S. Aamdal, I. Bondarenko, C. Robert, L. Thomas, and et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial J Clin Oncol 33 10 2015 1191 1196
5. S. Mocellin, C. Benna, and P. Pilati Coinhibitory molecules in cancer biology and therapy Cytokine Growth Factor Rev 24 2 2013 147 161
6. F.S. Hodi, S.J. O'Day, D.F. McDermott, R.W. Weber, J.A. Sosman, J.B. Haanen, and et al. Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 8 2010 711 723
7. C. Lebbe, J.S. Weber, M. Maio, B. Neyns, K. Harmankaya, O. Hamid, and et al. Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies Ann Oncol 25 11 2014 2277 2284
8. V. Shahabi, G. Whitney, O. Hamid, H. Schmidt, S.D. Chasalow, S. Alaparthy, and et al. Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab Cancer Immunol Immunother 61 5 2012 733 737
9. J.S. Weber, R. Dummer, V. de Pril, C. Lebbe, and F.S. Hodi Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma Cancer 119 9 2013 1675 1682
10. V. Barzey, M.B. Atkins, L.P. Garrison, Y. Asukai, S. Kotapati, and J.R. Penrod Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis J Med Econ 16 2 2013 202 212
11. S. Kelderman, B. Heemskerk, H. van Tinteren, R.R. van den Brom, G.A. Hospers, A.J. van den Eertwegh, and et al. Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma Cancer Immunol Immunother 63 5 2014 449 458
12. E. Simeone, G. Gentilcore, D. Giannarelli, A.M. Grimaldi, C. Caraco, M. Curvietto, and et al. Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma Cancer Immunol Immunother 63 7 2014 675 683
13. H. Schmidt, S. Suciu, C.J. Punt, M. Gore, W. Kruit, P. Patel, and et al. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial J Clin Oncol 25 12 2007 1562 1569
14. H. Joensuu Predicting recurrence-free survival after surgery for GIST Lancet Oncol 10 11 2009 1025
15. Y.M. Saenger, and J.D. Wolchok The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases Cancer Immun 8 2008 1
16. H. Schmidt, L. Bastholt, P. Geertsen, I.J. Christensen, S. Larsen, J. Gehl, and et al. Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model Br J Cancer 93 3 2005 273 278
17. S. Negrier, B. Escudier, F. Gomez, J.Y. Douillard, A. Ravaud, C. Chevreau, and et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie Ann Oncol 13 9 2002 1460 1468
18. J. Atzpodien, P. Royston, T. Wandert, and M. Reitz Metastatic renal carcinoma comprehensive prognostic system Br J Cancer 88 3 2003 348 353
19. C.A. Petrulio, S. Kim-Schulze, and H.L. Kaufman The tumour microenvironment and implications for cancer immunotherapy Expert Opin Biol Ther 6 7 2006 671 684
20. E.A. Vasievich, and L. Huang The suppressive tumor microenvironment: a challenge in cancer immunotherapy Mol Pharm 8 3 2011 635 641
21. P.J. Andrew, H. Harant, and I.J. Lindley Nitric oxide regulates IL-8 expression in melanoma cells at the transcriptional level Biochem Biophys Res Commun 214 3 1995 949 956
22. D. Schadendorf, A. Moller, B. Algermissen, M. Worm, M. Sticherling, and B.M. Czarnetzki IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor J Immunol 153 7 1994 3360
23. J. Norgauer, B. Metzner, and I. Schraufstatter Expression and growth-promoting function of the IL-8 receptor beta in human melanoma cells J Immunol 156 3 1996 1132 1137
24. P. Shamamian, J.D. Schwartz, B.J. Pocock, S. Monea, D. Whiting, S.G. Marcus, and et al. Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and proteinase-3: a role for inflammatory cells in tumor invasion and angiogenesis J Cell Physiol 189 2 2001 197 206
25. C.J. Gruss, K. Satyamoorthy, C. Berking, J. Lininger, M. Nesbit, H. Schaider, and et al. Stroma formation and angiogenesis by overexpression of growth factors, cytokines, and proteolytic enzymes in human skin grafted to SCID mice J Invest Dermatol 120 4 2003 683 692
26. S.P. Green, A. Chuntharapai, and J.T. Curnutte Interleukin-8 (IL-8), melanoma growth-stimulatory activity, and neutrophil-activating peptide selectively mediate priming of the neutrophil NADPH oxidase through the type A or type B IL-8 receptor J Biol Chem 271 41 1996 25400 25405
27. B. Weide, M. Elsasser, P. Buttner, A. Pflugfelder, U. Leiter, T.K. Eigentler, and et al. Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis Br J Cancer 107 3 2012 422 428
28. C.M. Balch, J.E. Gershenwald, S.J. Soong, J.F. Thompson, M.B. Atkins, D.R. Byrd, and et al. Final version of 2009 AJCC melanoma staging and classification J Clin Oncol 27 36 2009 6199 6206
29. S.L. Topalian, M. Sznol, D.F. McDermott, H.M. Kluger, R.D. Carvajal, W.H. Sharfman, and et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab J Clin Oncol 32 10 2014 1020 1030
30. P.B. Chapman, A. Hauschild, C. Robert, J.B. Haanen, P. Ascierto, J. Larkin, and et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 26 2011 2507 2516
31. C. Robert, B. Karaszewska, J. Schachter, P. Rutkowski, A. Mackiewicz, D. Stroiakovski, and et al. Improved overall survival in melanoma with combined dabrafenib and trametinib N Engl J Med 372 1 2015 30 39
32. C. Robert, A. Ribas, J.D. Wolchok, F.S. Hodi, O. Hamid, R. Kefford, and et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial Lancet 384 9948 2014 1109 1117
33. A. Hauschild, J.J. Grob, L.V. Demidov, T. Jouary, R. Gutzmer, M. Millward, and et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial Lancet 380 9839 2012 358 365